Africa’s Geographer Of Genes

Africa Is Emerging As A Test For The Proposition Technology-Driven Genomic Research Can Be A Business Worth Investing In

Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.

DNA strand
• Source: Alamy

As the world learns to live with COVID-19, one positive is the emergence of gene-sequencing technologies. Researchers now have a tool capable of tracking the spread of contagion throughout the biologic environment, in real time, thus offering the prospect of early, more targeted health interventions that prevent illness and save lives. Deconstructing the genome of a pathogen through human sample sequencing has led to a better understanding of viral transmissibility as well as the intensity of emerging mutations.

That is all to the good. But science alone is insufficient to ensure gene sequencing delivers actionable results at the...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

In Vivo’s 2026 Rising Leaders-Part 1

 
• By 

The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.

XXXXtesting

 
• By 

XXXXtesting